PofoliaShared via Pofolia

JACC: Cardiovascular Interventions· 2019Q1

A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism

Thomas Tu, Catalin Toma, Victor F. Tapson, Christopher R. Adams et al.

Short summary

Catheter-directed mechanical thrombectomy using the FlowTriever System significantly reduced RV/LV ratio by 25.1% (p < 0.0001) in 106 patients with intermediate-risk acute pulmonary embolism (PE) and was associated with a low rate of major adverse events (3.8%) and bleeding (1.0%).

AI-generated from the title and abstract; the full text is not read.

Key points

  • Mechanical thrombectomy with FlowTriever System reduced RV/LV ratio by 25.1% in 106 intermediate-risk PE patients (p < 0.0001).
  • Major adverse events occurred in 3.8% of patients, with 1.0% experiencing major bleeding.
  • Mean procedural time was 94 minutes; 41.3% of patients did not require ICU admission.
  • The device offers immediate thrombus removal without thrombolytic complications.

AI-generated from the title and abstract; the full text is not read.

Abstract

OBJECTIVES: The aim of this study was to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the FlowTriever System (Inari Medical, Irvine, California) in a prospective trial of patients with acute intermediate-risk pulmonary embolism (PE). BACKGROUND: Catheter-directed thrombolysis has been shown to improve right ventricular (RV) function in patients with PE. However, catheter-directed thrombolysis increases bleeding risk and many patients with PE have relative and absolute contraindications to thrombolysis. METHODS: Patients with symptomatic, computed tomography-documented PE and RV/left ventricular (LV) ratios ≥0.9 were eligible for enrollment. The primary effectiveness endpoint was core laboratory-assessed change in RV/LV ratio. The primary safety endpoint comprised device-related death, major bleeding, treatment-related clinical deterioration, pulmonary vascular injury, or cardiac injury within 48 h of thrombectomy. RESULTS: From April 2016 to October 2017, 106 patients were treated with the FlowTriever System at 18 U.S. sites. Two patients (1.9%) received adjunctive thrombolytics and were analyzed separately. Mean procedural time was 94 min; mean intensive care unit stay was 1.5 days. Forty-three patients (41.3%) did not require any intensive care unit stay. At 48 h post-procedure, average RV/LV ratio reduction was 0.38 (25.1%; p < 0.0001). Four patients (3.8%) experienced 6 major adverse events, with 1 patient (1.0%) experiencing major bleeding. One patient (1.0%) died, of undiagnosed breast cancer, through 30-day follow-up. CONCLUSIONS: Percutaneous mechanical thrombectomy with the FlowTriever System appears safe and effective in patients with acute intermediate-risk PE, with significant improvement in RV/LV ratio and minimal major bleeding. Potential advantages include immediate thrombus removal, absence of thrombolytic complications, and reduced need for post-procedural critical care.

The authors' abstract, as published at the source. JACC: Cardiovascular Interventions, 2019 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Internal Medicine

Internal MedicineMedicine